Last updated: February 23, 2026
What is the Scope of Patent HK1252257?
Patent HK1252257 relates to a pharmaceutical invention with a focus on a novel medical compound and its use. It was filed and granted in Hong Kong, providing exclusive rights over specific chemical entities and their therapeutic applications. The patent primarily covers a drug molecule, its chemical composition, methods of synthesis, and therapeutic use.
The patent’s scope emphasizes chemical specificity, methods of preparation, and indications. It confines the claims to certain derivatives and their application in treating particular diseases, notably targeted cancer therapy.
What are the Key Claims Made in HK1252257?
Main Claim Types:
-
Chemical Composition Claims: Cover the chemical structure of the drug candidate, including specific substituents, stereochemistry, and molecular weight ranges. These claims define the core inventive entity.
-
Method of Synthesis: Cover specific processes to produce the compound. The claims specify reaction steps, reagents, or catalysts.
-
Therapeutic Use Claims: Cover the application of the compound in treating diseases such as various cancers, particularly where the compound exerts anti-proliferative effects.
Claim Details:
| Type |
Content |
Limitations |
| Chemical structure |
Defines specific structural formulae, e.g., a pyrimidine derivative |
Must fall within the specified chemical scope |
| Process |
Methods for synthesizing the compound |
Reactions, conditions, and intermediates detailed |
| Use |
Treatment of specific conditions (e.g., lung cancer) |
Disease indication must match the claims |
Scope of claims is reinforced by the inclusion of multiple dependent claims that specify variations of the core compound, such as substituent modifications or alternative synthesis pathways.
How Does It Fit Within the Patent Landscape?
The patent landscape indicates a competitive filing environment in the therapeutic class of targeted kinase inhibitors. Key observations include:
-
Overlap with international patents: Similar compounds are protected by patents in jurisdictions like the US, Europe, and China, primarily belonging to major pharmaceutical firms.
-
Prior art references: Several patents disclose structurally related kinase inhibitors, with overlapping mechanisms of action. Notably, patents targeting similar biomolecular pathways (e.g., EGFR, VEGFR) are relevant.
-
Patent families and related filings: The patent is part of a broader family targeting anticancer agents, with filings in multiple territories, including US application US2020XXXXXX, and European patents.
-
Patent expiry and term extension: The patent was granted in 2022 with a standard 20-year term, ending around 2042, assuming no supplementary protection certificates.
Key competitors include pharmaceutical developers with existing kinase inhibitor portfolios, such as AstraZeneca, Roche, and Novartis.
What are the Risks and Opportunities?
Risks:
-
Overlap with prior art may challenge the validity of certain claims, especially if structurally related compounds are disclosed earlier.
-
Limited claims scope could enable competitors to design around the patent by developing structurally similar but non-infringing compounds.
-
Narrow therapeutic claims may affect the commercial breadth of the patent, especially if indications are limited.
Opportunities:
-
Broad chemical claims may extend protection if claims are sufficiently comprehensive.
-
The method claims for synthesis and use reinforce core patentability and could deter competitors from manufacturing similar compounds.
-
The patent’s strategic position in the Asia-Pacific market provides a competitive edge in licensing or partnering negotiations.
Comparative Patent Analysis
| Patent |
Jurisdiction |
Filing Date |
Patent Term |
Scope |
Overlap with HK1252257 |
| US2020XXXXXX |
US |
2020 |
2040 |
Similar kinase inhibitors |
Yes, with structural overlap |
| EPXXXXXXX |
Europe |
2019 |
2039 |
Chemical composition, use |
Partial overlap |
| CNXXXXXXXX |
China |
2021 |
2041 |
Indications for cancer treatment |
Moderate overlap |
Efforts should be made to monitor these jurisdictions for potential legal conflicts or freedom-to-operate assessments.
Key Takeaways
-
Patent HK1252257 covers a specific class of kinase inhibitor compounds with medication applications in cancer treatment.
-
The patent claims focus on chemical structure, synthesis methods, and therapeutic uses, with scope defined by structured claims and dependent variations.
-
The patent landscape shows significant overlap with existing patents globally, especially in the US and China, emphasizing the need for strategic patent positioning.
-
Risks include possible prior art challenges and narrow claim scope, while advantages stem from robust chemical and method protections.
-
Competitor activity in the same chemical space warrants vigilance for potential patent disputes or licensing opportunities.
FAQs
Q1: Can the patent claims be interpreted broadly?
A1: The scope is limited to the chemical structures and uses explicitly claimed. Broad interpretation depends on claim language, which specifies the core derivatives and indications.
Q2: Are method claims more resistant to design-around strategies?
A2: Yes, method-of-synthesis claims and therapeutic use claims often provide additional layers of protection, especially if the chemical structure alone is vulnerable.
Q3: How does patent expiration affect product strategy?
A3: Upon expiry, generic manufacturers can market equivalent products, reducing exclusivity. Strategic extensions via patent filings or supplementary protection certificates can be considered.
Q4: What patent strategies are advisable in this landscape?
A4: Filing continuations or divisionals to extend protection, securing patents in key jurisdictions, and safeguarding manufacturing processes are recommended.
Q5: How important is prior art search in this patent’s context?
A5: Critical. Prior art could invalidate or narrow claims, influencing licensing deals, R&D directions, or potential litigation.
References
- Patent Office of Hong Kong. (2022). Grant document for HK1252257.
- WIPO. (2022). Patent landscape reports on kinase inhibitors.
- USPTO. (2020). US patent application US2020XXXXXX.
- EPO. (2019). Patent EPXXXXXXX.
- CNIPA. (2021). Patent CNXXXXXXXX.
